tuvutromstat   Click here for help

GtoPdb Ligand ID: 14409

Synonyms: compound 167 [US11046691] | GSK-4362676 | GSK4362676 | IDE-397 | IDE397
Compound class: Synthetic organic
Comment: IDE397 is a methionine adenosyltransferase 2A (MAT2A) inhibitor [1-3]. It was designed to target the MAT2A-SAM axis and induce synthetic lethal effects in MTAP-deleted tumours. The chemical structure was matched to that for the INN tuvutromstat, as disclosed in WHO INN Proposed List 135 (July 2026).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 71.05
Molecular weight 340.69
XLogP 1.03
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=C(C=C1)N2C3=C(C=CC(=N3)C(F)(F)F)C(=NC2=O)N)Cl
Isomeric SMILES C1=CC=C(C(=C1)N2C3=C(C=CC(=N3)C(F)(F)F)C(=NC2=O)N)Cl
InChI InChI=1S/C14H8ClF3N4O/c15-8-3-1-2-4-9(8)22-12-7(11(19)21-13(22)23)5-6-10(20-12)14(16,17)18/h1-6H,(H2,19,21,23)
InChI Key BVNKURJMNQNVAO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
IDE397 was progressed as a clinical candidate for the treatment of MTAP-deleted solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04794699 Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion Phase 1 Interventional IDEAYA Biosciences
NCT05975073 A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors Phase 1/Phase 2 Interventional Amgen
NCT07277413 A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors Phase 1 Interventional IDEAYA Biosciences